Non-Steroidal Anti-Inflammatory Drugs Market, By Type (paracetamol, Ibuprofen, aspirin, naproxen, and others), By disease indication (Arthritis, Migraine, ophthalmic and others), By Route of administration (Oral and Parenteral), By Application (Hospital Pharmacy, Retail pharmacy and Online Pharmacy) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030

Anti-inflammatory medications are prescribed to treat disorders such as asthma, arthritis, chronic obstructive pulmonary disorder (COPD), and others. The rising prevalence of these diseases is the primary driver of market growth. Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used to treat pain and inflammation. These have become the most widely used medicines around the world as the number of prescriptions has increased. Because of three essential properties: analgesic, antipyretic, and anti-inflammatory, these are considered the first line of treatment in pain management. Nonsteroidal anti-inflammatory drugs (NSAIDs) have been used to treat pain since the 1960s and 1970s when the FDA approved the first few main molecules including diclofenac and ibuprofen. The Non-Steroidal Anti-Inflammatory Drugs Market accounted for US$ 16.4 billion in 2020 and is estimated to be US$ 28.7 billion by 2030 and is anticipated to register a CAGR of 6.0%.

Impact of Covid-19 pandemic on market

The COVID-19 outbreak has brought the entire world to a halt. Rising government and corporate funding could aid in the battle against this highly contagious disease. The pandemic is expected to have an effect on almost every industry. Chronic pain has a significant health and economic impact due to lost efficiency and medication costs.

Rising initiatives by government bodies

Inflammation and pain-causing conditions are becoming more common every day across the world. It is increasing the use of nonsteroidal anti-inflammatory drugs (NSAIDs) to cure and treat chronic and acute pain. Diclofenac and ibuprofen are the most widely prescribed pain relievers. Several countries' governments are taking steps to reduce the cost of diagnosing and treating chronic pain. NSAIDs, on the other hand, can cause a variety of side effects, including dizziness, stomach aches, ulcers, and allergic reactions. It has the potential to stifle business expansion.

Growth in business operations by emerging and small sized players

The global demand for non-steroidal anti-inflammatory drugs is expected to expand rapidly in the coming years, owing to significant investments in product R&D. One of the major factors driving the growth of the non-steroidal anti-inflammatory drugs market is the rising prevalence of pain and inflammation-causing diseases. The use of these medications to treat acute and chronic pain is increasing. The increasing prevalence of bone and joint disorders such as rheumatoid arthritis and osteoarthritis, as well as a rise in the number of hospital operations, are expected to drive the bone and joint pain segment. The demand for non-steroidal anti-inflammatory drugs is expected to rise due to rising prevalence of pain disorders, an increase in the geriatric population at high risk of various diseases, the acceptance of pain management therapeutics by end-users, and favorable regulatory and health-care reforms.

The non Steroidal anti-inflammatory drugs market is segmented based on type, disease indication, route of administration, application, and region.

On the basis of type, the non steroidal anti-inflammatory drugs market is segmented into paracetamol, Ibuprofen, Aspirin, naproxen and others. Based on disease indication, the target market is segmented into arthritis, migraine, ophthalmic and others. On the basis of route of administration, the market is segmented into oral and parenteral. On the basis of application, the target market is segmented into hospital pharmacy, retail pharmacy and online pharmacy.

Regional Insights:

On region the non Steroidal anti-inflammatory drugs market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Europe, on the other hand, is projected to rise steadily, owing to favorable health reimbursement policies, a higher prevalence of migraine, and active government support. The rising use of over-the-counter NSAIDs and the growing geriatric population in Asia Pacific are expected to boost growth.

Report Scope:

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2019 to 2030. For the purpose of this study, has segmented the non-steroidal anti-inflammatory drugs market report based on type, disease indication, route of administration, application, and region.

Non Steroidal Anti-inflammatory drugs Market, By Region:

• • • North America
      • • U.S.
        • Canada
    • Europe
      • • Germany
        • UK
        • France
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • • China
        • India
        • Japan
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • • GCC
        • Israel
        • South Africa
        • Rest of Middle East & Africa

The key players operating in the non steroidal anti-inflammatory drugs market include GlaxoSmithKline plc, Johnson & Johnson Services, Inc., Pfizer Inc., Boehringer Ingelheim International GmbH, AstraZeneca, Bayer AG, Horizon Therapeutics plc, Zyla Life Sciences and other key players. GSK accounted for the largest share of the demand for non-steroidal anti-inflammatory drugs (NSAIDs). As several new players strive to enter the market through new product releases and strategic alliances, competition in the market is steadily growing.

• GlaxoSmithKline plc,
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

• Johnson a d Johnson services
• Pfizer Inc.
• Boehringer Ingelheim International GmbH,
• AstraZeneca
• Bayer AG
• Horizon Therapeutics plc
• Zyla Life Sciences
• Others

“*” marked represents similar segmentation in other categories in the respective section